Fatty Liver Disease and Hepatocellular Carcinoma: The Pathologist's View

被引:10
作者
Tiniakos, Dina G. [1 ,2 ]
Mauricio, Joao [3 ]
Reeves, Helen L. [3 ]
机构
[1] Newcastle Univ, Inst Cellular Med, Fac Med Sci, Newcastle Upon Tyne, Tyne & Wear, England
[2] Natl & Kapodistrian Univ Athens, Dept Pathol, Aretaie Hosp, Sch Med, Athens, Greece
[3] Newcastle Univ, Northern Inst Canc Res, Newcastle Upon Tyne, Tyne & Wear, England
来源
ALCOHOL AND CANCER | 2018年 / 1032卷
关键词
Alcoholic; Nonalcoholic; Fatty Liver Disease; Steatohepatitis; Hepatocellular Carcinoma; Histopathology; Pathogenesis; Diagnosis; HEPATITIS-C VIRUS; NONALCOHOLIC STEATOHEPATITIS; RISK-FACTORS; METABOLIC SYNDROME; ALCOHOLIC CIRRHOSIS; VIRAL-HEPATITIS; NATURAL-HISTORY; HEAVY DRINKERS; CELL CHANGE; OBESITY;
D O I
10.1007/978-3-319-98788-0_4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Chronic alcohol misuse and progressed nonalcoholic fatty liver disease (NAFLD) due to the metabolic syndrome and resulting to nonalcoholic steatohepatitis (NASH) are prime causes of hepatocellular carcinoma (HCC) in Western industrialized countries. The incidence of HCC in NASH-cirrhosis is lower than that of HCC occuring in HCV-related or alcoholic cirrhosis. Up to 20% of cases of alcohol-associated HCC may develop in pre-cirrhotic liver while HCC is also increasingly recognised in pre-cirrhotic NASH raising questions on appropriate surveillance measures for these patient populations. The recently described steatohepatitic subtype of HCC presents with higher frequency in NAFLD compared to alcoholic liver disease (ALD) patients. This review will mainly focus on histopathology and summarize current data on the epidemiology, pathogenesis, diagnosis and management of NAFLD- and ALD-related HCC.
引用
收藏
页码:55 / 69
页数:15
相关论文
共 89 条
[1]   Hepatocellular carcinomas with intracellular hyaline bodies have a poor prognosis [J].
Aigelsreiter, Ariane ;
Neumann, Jens ;
Pichler, Martin ;
Halasz, Judith ;
Zatloukal, Kurt ;
Berghold, Andrea ;
Douschan, Philipp ;
Rainer, Florian ;
Stauber, Rudolf ;
Haybaeck, Johannes ;
Denk, Helmut ;
Lackner, Carolin .
LIVER INTERNATIONAL, 2017, 37 (04) :600-610
[2]   Non-alcoholic fatty liver disease contributes to hepatocarcinogenesis in non-cirrhotic liver: A clinical and pathological study [J].
Alexander, Jacob ;
Torbenson, Michael ;
Wu, Tsung-Teh ;
Yeh, Matthew M. .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2013, 28 (05) :848-854
[3]  
[Anonymous], J CLIN ONCOL S
[4]  
[Anonymous], J CLIN ONCOL S
[5]   Genetic Factors That Affect Risk of Alcoholic and Nonalcoholic Fatty Liver Disease [J].
Anstee, Quentin M. ;
Seth, Devanshi ;
Day, Christopher P. .
GASTROENTEROLOGY, 2016, 150 (08) :1728-+
[6]   The Incidence and Risk Factors of Hepatocellular Carcinoma in Patients with Nonalcoholic Steatohepatitis [J].
Ascha, Mustafa S. ;
Hanouneh, Ibrahim A. ;
Lopez, Rocio ;
Tamimi, Tarek Abu-Rajab ;
Feldstein, Ariel F. ;
Zein, Nizar N. .
HEPATOLOGY, 2010, 51 (06) :1972-1978
[7]   Hepatocellular carcinoma in non-alcoholic fatty liver disease: An emerging menace [J].
Baffy, Gyoergy ;
Brunt, Elizabeth M. ;
Caldwell, Stephen H. .
JOURNAL OF HEPATOLOGY, 2012, 56 (06) :1384-1391
[8]   AFP, PIVKAII, GP3, SCCA-1 and follisatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver disease [J].
Beale, Gary ;
Chattopadhyay, Dipankar ;
Gray, Joe ;
Stewart, Stephen ;
Hudson, Mark ;
Day, Christopher ;
Trerotoli, Paolo ;
Giannelli, Gianluigi ;
Manas, Derek ;
Reeves, Helen .
BMC CANCER, 2008, 8 (1)
[9]   Role of the GALAD and BALAD-2 Serologic Models in Diagnosis of Hepatocellular Carcinoma and Prediction of Survival in Patients [J].
Berhane, Sarah ;
Toyoda, Hidenori ;
Tada, Toshifumi ;
Kumada, Takashi ;
Kagebayashi, Chiaki ;
Satomura, Shinji ;
Schweitzer, Nora ;
Vogel, Arndt ;
Manns, Michael P. ;
Benckert, Julia ;
Berg, Thomas ;
Ebker, Maria ;
Best, Jan ;
Dechene, Alexander ;
Gerken, Guido ;
Schlaak, Joerg F. ;
Weinmann, Arndt ;
Worns, Marcus A. ;
Galle, Peter ;
Yeo, Winnie ;
Mo, Frankie ;
Chan, Stephen L. ;
Reeves, Helen ;
Cox, Trevor ;
Johnson, Philip .
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2016, 14 (06) :875-+
[10]   Efficacy and safety of regorafenib versus placebo in patients with hepatocellular carcinoma (HCC) progressing on sorafenib: results of the international, randomized phase 3 RESORCE trial [J].
Bruix, J. ;
Merle, P. ;
Granito, A. ;
Huang, Y. -H. ;
Bodoky, G. ;
Yokosuka, O. ;
Rosmorduc, O. ;
Breder, V. ;
Gerolami, R. ;
Masi, G. ;
Paul, J. Ross ;
Qin, S. ;
Song, T. ;
Bronowicki, J. -P. ;
Ollivier-Hourmand, I. ;
Kudo, M. ;
LeBerre, M. -A. ;
Baumhauer, A. ;
Meinhardt, G. ;
Han, G. .
ANNALS OF ONCOLOGY, 2016, 27 :140-+